|
|
Post by longliner on Nov 3, 2023 9:53:53 GMT -5
Mannkind made a change nine weeks ago to Afrezza that changed the sales trajectory. We all see the scripts every week. It became clear after
the first couple weeks that something had changed the trajectory of scrips, not just compared to this year but past sales patterns as well.
I expect clarification at or before this earnings report.
Did the "invest in growth" model find a more profitable direction?
|
|
|
|
Post by cretin11 on Nov 3, 2023 10:21:31 GMT -5
I expect clarification at or before this earnings report. Did the "invest in growth" model find a more profitable direction? Agree we should expect clarification at or before the earnings report. The “invest in growth” may indeed be out, let’s just hope “rest and grow” is not in! |
|
|
|
Post by sayhey24 on Nov 3, 2023 10:25:59 GMT -5
Mannkind made a change nine weeks ago to Afrezza that changed the sales trajectory. We all see the scripts every week. It became clear after the first couple weeks that something had changed the trajectory of scrips, not just compared to this year but past sales patterns as well. I expect clarification at or before this earnings report. Did the "invest in growth" model find a more profitable direction? Whats your theory? Are more PWDs moving to afrezza assist? Are Medicare pre auths getting a higher rejection rate? Did something happen to the sales staff? |
|
|
|
Post by cretin11 on Nov 3, 2023 11:47:42 GMT -5
A possibility we've long speculated is that a higher percentage of scripts will not be captured by Symphony, so the "real" script numbers are much better than the anemic figures we're seeing. As far as i know our only way to assess this is to basically reverse engineer it from the reported numbers. My recollection is last time we did that it was not encouraging as it seemed Symphony was in fact capturing almost everything. Looking forward to the new numbers and hoping (though admittedly not expecting) that metric will be more encouraging this time.
|
|
|
|
Post by Clement on Nov 3, 2023 11:56:38 GMT -5
Mannkind made a change nine weeks ago to Afrezza that changed the sales trajectory. We all see the scripts every week. It became clear after the first couple weeks that something had changed the trajectory of scrips, not just compared to this year but past sales patterns as well. I expect clarification at or before this earnings report. Did the "invest in growth" model find a more profitable direction? Maybe Mike slashed some expenses (salaries, travel, freebies, shows, etc) as the deadline for endocrine CFBE approaches. |
|
|
|
Post by awesomo on Nov 3, 2023 12:15:29 GMT -5
Mannkind made a change nine weeks ago to Afrezza that changed the sales trajectory. We all see the scripts every week. It became clear after the first couple weeks that something had changed the trajectory of scrips, not just compared to this year but past sales patterns as well. I expect clarification at or before this earnings report. Did the "invest in growth" model find a more profitable direction? Unless you want to back this up with evidence, it sounds like you're just making excuses for the weak script numbers. |
|
|
|
Post by longliner on Nov 3, 2023 12:19:41 GMT -5
Mannkind made a change nine weeks ago to Afrezza that changed the sales trajectory. We all see the scripts every week. It became clear after the first couple weeks that something had changed the trajectory of scrips, not just compared to this year but past sales patterns as well. I expect clarification at or before this earnings report. Did the "invest in growth" model find a more profitable direction? Whats your theory? Are more PWDs moving to afrezza assist? Are Medicare pre auths getting a higher rejection rate? Did something happen to the sales staff? My honest answer is I have know idea, hence I'm looking forward to the explanation. I recall Mike stating that this year he was tasked with making Afrezza break even or profitable I don't recall which. It's possible this drove some directional change nine weeks ago. The growth in Technosphere for indications beyond Afrezza has to fit into the equation somehow. As I stated before, we are seeing huge movement on the M&A front and at any point this may come into play. Each indication we advance, makes MNKD a more attractive target. |
|
|
|
Post by hellodolly on Nov 5, 2023 8:07:40 GMT -5
I went back to the last 10Q (page 17) reported for Q2 and read this regarding V-GO:
"For the three and six months ended June 30, 2023, net revenue for V-Go was $4.8 million and $10.0 million, respectively, and loss from operations was $0.5 million and $1.5 million, respectively. For each of the three and six month periods ended June 30, 2022, net revenue and loss from operations for V-Go was $2.1 million and $0.3 million, respectively."
Can anyone elaborate more? I read somewhere that V-GO is not making any money, we purchased it for $15.951M with $11M of the cost applying to inventory. Are the smaller losses reported from operations due to the large supply of inventory still on hand? Is this becoming profitable?
|
|
|
|
Post by awesomo on Nov 5, 2023 10:27:54 GMT -5
I went back to the last 10Q (page 17) reported for Q2 and read this regarding V-GO: "For the three and six months ended June 30, 2023, net revenue for V-Go was $4.8 million and $10.0 million, respectively, and loss from operations was $0.5 million and $1.5 million, respectively. For each of the three and six month periods ended June 30, 2022, net revenue and loss from operations for V-Go was $2.1 million and $0.3 million, respectively."Can anyone elaborate more? I read somewhere that V-GO is not making any money, we purchased it for $15.951M with $11M of the cost applying to inventory. Are the smaller losses reported from operations due to the large supply of inventory still on hand? Is this becoming profitable? There’s nothing really to elaborate, “loss from operations” means this is losing money, regardless of net revenue. They are telling you V-Go is unprofitable. |
|
|
|
Post by akemp3000 on Nov 5, 2023 10:57:14 GMT -5
Everyone would agree it's been unprofitable to date. The question or elaboration is whether or not MC will say if and when it will become profitable. There's a lot we need to hear this coming week.
|
|
|
|
Post by cretin11 on Nov 5, 2023 11:51:21 GMT -5
Everyone would agree it's been unprofitable to date. The question or elaboration is whether or not MC will say if and when it will become profitable. There's a lot we need to hear this coming week. Not sure everyone agrees VGo has been unprofitable so far. I recall seeing posts here claiming it “paid for itself” within months, but those posts may have been retracted once they understood the actual numbers. Agree there’s a lot we need to hear and hope we will this week. |
|
|
|
Post by wyattdog on Nov 5, 2023 13:49:50 GMT -5
Fun factoid. 4.8 million net revenue for V-Go for the 3 months ending June 30. That’s the same revenue as Liguida had for the 3 months ending June 30.
|
|
|
|
Post by hellodolly on Nov 6, 2023 6:21:45 GMT -5
I went back to the last 10Q (page 17) reported for Q2 and read this regarding V-GO: "For the three and six months ended June 30, 2023, net revenue for V-Go was $4.8 million and $10.0 million, respectively, and loss from operations was $0.5 million and $1.5 million, respectively. For each of the three and six month periods ended June 30, 2022, net revenue and loss from operations for V-Go was $2.1 million and $0.3 million, respectively."Can anyone elaborate more? I read somewhere that V-GO is not making any money, we purchased it for $15.951M with $11M of the cost applying to inventory. Are the smaller losses reported from operations due to the large supply of inventory still on hand? Is this becoming profitable? There’s nothing really to elaborate, “loss from operations” means this is losing money, regardless of net revenue. They are telling you V-Go is unprofitable. OK. Net-net it's a loss of .5 and 1.5. So, the line reports revenue and it concludes with net-net. Gotcha, in this case a loss. |
|
|
|
Post by awesomo on Nov 6, 2023 10:43:53 GMT -5
Fun factoid. 4.8 million net revenue for V-Go for the 3 months ending June 30. That’s the same revenue as Liguida had for the 3 months ending June 30. The difference is one is viewed with upside, the other is completely stagnant and has been for years. |
|
|
|
Post by beardawg on Nov 6, 2023 10:57:46 GMT -5
will buy more shares if the price dips well into the 3's, but I'm not going to like it (or tell my wife)... Haha, yes the “buying more shares but not telling spouse” has been a theme on this message board going back at least seven or eight years. All of us who’ve done it figured “soon I’ll tell them, once our share price goes back up to _____, which should only be a year or two.” Now I can’t wait to say “those MNKD shares I bought back in 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021 and 2022, I didn’t mention it then but KNEW it was a great investment decision and now look how smart I was all along!” Was hoping 2023 would be that phenomenal year, oh well. We can remember what the Brooklyn Dodgers fans would say after every season… If you bought in 2019, you're golden. Even at it's peak, the highest share price was ~$2.20. |
|
